Product image of Maraviroc supplied by GNH India

Maraviroc

Active Ingredient:
Maraviroc
Origin:
EU

Maraviroc

Maraviroc, the active ingredient in Maraviroc, is a CCR5 antagonist presented as a 150 mg tablet for oral use. It treats HIV‑1 infection in adults by preventing viral entry into host cells.

GNH India supplies Maraviroc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Waymade Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maraviroc is indicated for the treatment of HIV‑1 infection, specifically targeting viruses that use the CCR5 co‑receptor.

  • HIV‑1 infection (CCR5‑tropic): Used in combination with other antiretrovirals to suppress viral replication in adults.
  • Treatment‑experienced HIV‑1 infection: Added to regimens when resistance to other agents has developed.
  • Treatment‑naïve CCR5‑tropic HIV‑1 infection: Initiated as part of first‑line therapy in patients with confirmed CCR5‑tropic virus.

How It Works

  • Maraviroc binds selectively to the CCR5 chemokine receptor on the surface of CD4+ T cells and macrophages, blocking the receptor’s interaction with the HIV‑1 envelope glycoprotein gp120. This inhibition prevents the virus from attaching to and entering host cells, thereby halting replication of CCR5‑tropic HIV‑1 strains.

Side Effects

Maraviroc may cause a range of adverse reactions, from mild to serious. Monitoring and reporting of side effects are essential for patient safety.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional, may improve with food.
  • Diarrhea: usually self‑limiting.
  • Fatigue: persistent low‑grade tiredness.
  • Upper respiratory tract infection: symptoms of cold or sinusitis.
  • Rash: non‑specific skin eruption.

Serious or Rare Side Effects

  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Severe allergic reaction: anaphylaxis, angioedema.
  • Depression or suicidal thoughts: mood changes requiring evaluation.
  • Cardiovascular events: myocardial infarction or arrhythmia.
  • Immune reconstitution inflammatory syndrome (IRIS): worsening of opportunistic infections.
  • Pulmonary complications: interstitial lung disease.

Precautions & Warnings

Before initiating therapy with Maraviroc, clinicians should assess patient history and monitor for potential risks.

  • Liver function monitoring: check transaminases regularly during treatment.
  • Cardiovascular assessment: evaluate for underlying heart disease before use.
  • Hypersensitivity screening: avoid in patients with known allergy to maraviroc.
  • Renal impairment caution: dose adjustment may be required in severe renal dysfunction.
  • Drug‑resistance testing: confirm CCR5‑tropic virus prior to prescribing.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Maraviroc interacts with several agents that affect its metabolism or efficacy.

Major Interactions (Avoid)

  • Ritonavir (strong CYP3A4 inhibitor): markedly increases maraviroc plasma concentrations.
  • Enzalutamide (strong CYP3A4 inducer): significantly reduces maraviroc exposure.

Moderate Interactions (Monitor Closely)

  • Efavirenz (moderate CYP3A4 inducer): may lower maraviroc levels.
  • Atazanavir (CYP3A4 inhibitor): can increase maraviroc concentrations.
  • Phenytoin (CYP3A4 inducer): may decrease maraviroc effectiveness.

Frequently Asked Questions

Maraviroc is an antiretroviral medication used to treat HIV‑1 infection in adults. It is prescribed as part of combination therapy for patients whose virus uses the CCR5 co‑receptor, helping to suppress viral replication and improve immune function.

Maraviroc blocks the CCR5 chemokine receptor on CD4+ T cells and macrophages, preventing the HIV‑1 envelope protein gp120 from binding. This inhibition stops the virus from entering host cells, thereby reducing the spread of CCR5‑tropic HIV‑1 strains.

The specific dose of Maraviroc is determined by the prescribing clinician based on the patient’s viral load, resistance profile, and concomitant medications. Dosage adjustments may be needed for renal or hepatic impairment, and the regimen is individualized for each patient.

Safety data for Maraviroc in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Maraviroc, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maraviroc belongs to the CCR5 antagonist class, which differs from protease inhibitors, nucleoside reverse transcriptase inhibitors, and integrase inhibitors. Its unique mechanism targets viral entry rather than replication, offering an alternative for patients with resistance to other drug classes or when a CCR5‑tropic virus is confirmed.

Maraviroc tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Maraviroc is taken orally, usually with food to improve absorption. The tablet should be swallowed whole with a glass of water and taken at the same times each day as directed by the prescriber.

Serious risks include liver injury, severe allergic reactions such as anaphylaxis, depression or suicidal thoughts, cardiovascular events, and immune reconstitution inflammatory syndrome. Patients should be monitored regularly for these events, and any concerning symptoms should be reported promptly.

Maraviroc is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be avoided in individuals whose HIV‑1 virus does not use the CCR5 co‑receptor, as the medication would be ineffective.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Maraviroc

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT